Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis in… (NCT06980493) | Clinical Trial Compass
Active — Not RecruitingPhase 2/3
Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis in Children 16 Years Old or Less we Follow up Cases Weekly up to 8 Weeks and Notice Improvement of Itching ,Scaling, and Hair Regrowth Then Fungal Culture Done to See if the Solution Working
Egypt30 participantsStarted 2025-04-01
Plain-language summary
The goal of this clinical trial is to learn if topical amphotericin b solution works to treat resistant cases of tinea capitis in children. It will also learn about the safety of drug. The main questions it aims to answer are:
Does amphotericin b solution effective in cases not cured by systemic antifungal tab?
Participants will:
use topical amphotericin b solution every day for8 weeks Visit the clinic once every 1 week for follow up then follow up after 1 month and fungal culture will be done to test if the treatment working
Who can participate
Age range
0 Days – 16 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Children aged \< 16 years affected by tinea capitis non inflammatory type who are clinically and dermoscopically confirmed after resistant response to oral systemic treatment for 8 weeks.
Exclusion Criteria:
* Patients with inflammatory tinea capitis, kerion or favus. Patients with known hypersensitivity to amphotericin B, other systemic conditions or ongoing use of conflicting medications.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial is testing a topical amphotericin B solution — which is applied directly to the scalp rather than taken by mouth — is a topical treatment likely to be enough for my child's resistant tinea capitis, or would an oral antifungal still be a safer first step?
2This is a Phase 2/3 trial, meaning researchers are still gathering evidence on how well and how safely this solution works in children — what do you know so far about any side effects seen in kids using this topical amphotericin B?
3The trial tracks improvement weekly for 8 weeks and uses fungal cultures to confirm results — if we were to consider this, how disruptive would those weekly check-ins be, and is that level of monitoring realistic for our schedule?
4Since the trial is active but no longer recruiting new participants, does that mean there are any early findings or interim results you've seen that could help us decide whether this approach makes sense for my child?
5Given that this trial is specifically for resistant tinea capitis cases, does my child's infection actually meet the definition of 'resistant,' and have we already tried the standard treatments that would normally come before exploring a study like this?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
monitoring for reduction in size of scaling weekly for 8 weeks